Patrick AebischerPatrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Françoise Gisou van der Goot GrunbergGisou van der Goot is the Head of the Laboratory of Cell and Membrane Biology, and founding member of the Global Health Institute (GHI), School of Life Sciences, at the Swiss Federal Institute of Technology Lausanne/EPFL (Ecole Polytechnique Fédérale de Lausanne). She is currently Vice President for Responsible Transformation, in charge of reinforcing values such as inclusion and sustainability throughout the School’s campus. From 2014 to 2020, she was Dean of the School of Life Sciences. Before joining EPFL, she was Group Leader at the Faculty of Sciences of the University of Geneva (UNIGE) and subsequently Associate Professor at the Faculty of Medicine of the same university. She studied engineering at the Ecole Centrale de Paris, then did a PhD in Molecular Biophysics at the Nuclear Energy Research Center, Saclay, France, followed by a postdoc at the European Molecular Biology Laboratory (EMBL) in Heidelberg. She obtained an EMBO Young Investigator award in 2001, a Howard Hughes International Scholar award in 2005 and the Swiss Prix Marcel Benoist in 2009, the same year she was elected EMBO member (European Molecular Biology Organisation). She is a leader in the fields of molecular and cellular understanding of bacterial toxins, the organization of mammalian membranes and in organelles biology. Professor van der Goot is member of diverse scientific boards such as the Swiss National Science Foundation (SNF), the Conseil suisse de la science et de la technologie (CSST) and the European Research Council (ERC).
John McKinneyProfessor John McKinney received his Ph.D. from The Rockefeller University (New York, NY) in 1994 for studies on cell cycle regulation in
Saccharomyces cerevisiae
in the laboratory of Fred Cross. From 1995 to 1998, he was a postdoctoral fellow in the laboratory of William Jacobs at the Albert Einstein College of Medicine (Bronx, NY), where he studied mechanisms of persistence in
Mycobacterium tuberculosis
. In 1999, he returned to Rockefeller University to establish his own laboratory as an Assistant (1999-2004) and then Associate (2004-2007) Professor. In July 2007, the lab relocated to the Global Health Institute in the School of Life Sciences at the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, where McKinney is Professor and Head of the Laboratory of Microbiology and Microsystems (LMIC). Our research focuses on understanding the mechanistic basis of bacterial persistence in the context of host immunity and antimicrobial therapy, using
M. tuberculosis
as a "model" system.
Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
Dominique PiolettiDominique Pioletti received his Master in Physics from the Swiss Federal Institute of Technology Lausanne (EPFL) in 1992. He pursued his education in the same Institution and obtained his PhD in biomechanics in 1997. He developed original constitutive laws taking into account viscoelasticity in large deformations. Then he spent two years at UCSD as post-doc fellow acquiring know-how in cell and molecular biology. He was interested in particular to gene expression of bone cells in contact to orthopedic implant. In April 2006, Dominique Pioletti was appointed Assistant Professor tenure-track at the EPFL and is director of the Laboratory of Biomechanical Orthopedics. His research topics include biomechanics and tissue engineering of musculo-skeletal tissues; mechano-transduction in bone; development of orthopedic implant as drug delivery system. Since 2013, he has been promoted to the rank of Associate Professor.
Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Freddy RadtkeFreddy Radtke obtained his Ph.D. in Molecular Biology from the University of Zürich in 1994. In 1995, he started his postdoctoral research in the laboratory of Michel Aguet at Genentech, Inc. (San Francisco, USA). In 1997, he returned to Switzerland with Michel Aguet and finished his postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. From 1999‑2005, he was a group leader and Associate Member at the Ludwig Institute for Cancer Research. Freddy Radtke then joined ISREC in January 2006 as a senior scientist and in July 2006, he was appointed Associate Professor at the EPFL School of Life Sciences
Jacques FellayJacques Fellay is a medical scientist with expertise in infectious diseases and human genomics. He obtained his MD from the University of Lausanne in 2002 and his PhD from University of Utrecht. After a clinical training in infectious diseases in Switzerland and a 4-years postdoctoral fellowship at Duke University, he joined the EPFL in April 2011 with an SNF Professorship.
On top of his EPFL affiliation, Jacques is also Head of Precision Medicine at the University Hospital (CHUV) in Lausanne, Group Leader at the Swiss Institute of Bioinformatics, and Co-director of the Health2030 Genome Center at Campus Biotech in Geneva.
